Home Halogens [(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate

[(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate

CAS No.:
27848-84-6
Catalog Number:
AG00I58H
Molecular Formula:
C24H26BrN3O3
Molecular Weight:
484.3855
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
98%powder
In Stock USA
United States
$60
- +
100mg
95%
In Stock USA
United States
$75
- +
250mg
95%
In Stock USA
United States
$125
- +
500mg
98%powder
In Stock USA
United States
$226
- +
1g
98%powder
In Stock USA
United States
$396
- +
Product Description
Catalog Number:
AG00I58H
Chemical Name:
[(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate
CAS Number:
27848-84-6
Molecular Formula:
C24H26BrN3O3
Molecular Weight:
484.3855
MDL Number:
MFCD00869626
IUPAC Name:
[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
InChI:
InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
InChI Key:
YSEXMKHXIOCEJA-FVFQAYNVSA-N
SMILES:
CO[C@]12C[C@@H](COC(=O)c3cncc(c3)Br)CN([C@@H]1Cc1c3c2cccc3n(c1)C)C
EC Number:
248-694-6
UNII:
JCV8365FWN
NSC Number:
757853
Properties
Complexity:
681  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
3  
Defined Bond Stereocenter Count:
0
Exact Mass:
483.116g/mol
Formal Charge:
0
Heavy Atom Count:
31  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
484.394g/mol
Monoisotopic Mass:
483.116g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
56.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.2  
Literature
Title Journal
Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS computational biology 20120201
Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients. Clinical rheumatology 20120101
Systematic review on the efficacy and safety of herbal medicines for vascular dementia. Evidence-based complementary and alternative medicine : eCAM 20120101
Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. International journal of Alzheimer's disease 20120101
Characterization of nicergoline polymorphs crystallized in several organic solvents. Journal of pharmaceutical sciences 20110701
Nicergoline improves dysphagia by upregulating substance P in the elderly. Medicine 20110701
New therapeutic approaches in the treatment of diabetic keratopathy: a review. Clinical & experimental ophthalmology 20110401
Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties. Naunyn-Schmiedeberg's archives of pharmacology 20110101
The effects of intrathecal nicergoline and nimodipine in cerebral vasospasm: an experimental study in rabbits. Acta neurochirurgica. Supplement 20110101
The effects of nicergoline on corneal nerve regeneration in rat corneas after photorefractive keratectomy. Current eye research 20110101
Validated stability-indicating spectrofluorimetric methods for the determination of ebastine in pharmaceutical preparations. Chemistry Central journal 20110101
Dysthymia and apathy: diagnosis and treatment. Depression research and treatment 20110101
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters 20101101
Colloid formation by drugs in simulated intestinal fluid. Journal of medicinal chemistry 20100527
Nicergoline increases serum substance P levels in patients with an ischaemic stroke. Cerebrovascular diseases (Basel, Switzerland) 20100101
Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. Journal of neuroinflammation 20100101
A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full. Trials 20100101
[Therapeutic potential and possibilities of using of sermion (nicergoline) in neurological practice]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101
Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. The Annals of pharmacotherapy 20090701
Natural non-trasgenic animal models for research in Alzheimer's disease. Current Alzheimer research 20090401
Effects of nicergoline on corneal epithelial wound healing in rat eyes. Investigative ophthalmology & visual science 20090201
[Glaucoma--neurodegenerative disease]. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20090101
Vascular cognitive impairment. Indian journal of psychiatry 20090101
Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21. Journal of neurochemistry 20080501
Method development and validation for the simultaneous determination of cinnarizine and co-formulated drugs in pharmaceutical preparations by capillary electrophoresis. Journal of pharmaceutical and biomedical analysis 20080213
Smart stability-indicating spectrophotometric methods for determination of binary mixtures without prior separation. Journal of AOAC International 20080101
Second-derivative synchronous fluorescence spectroscopy for the simultaneous determination of cinnarizine and nicergoline in pharmaceutical preparations. Journal of AOAC International 20080101
Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids. Neurotoxicology and teratology 20080101
Therapeutic use of nicergoline. Clinical drug investigation 20080101
Progress update: Pharmacological treatment of Alzheimer's disease. Neuropsychiatric disease and treatment 20071001
Vascular dementia: pharmacological treatment approaches and perspectives. Clinical interventions in aging 20070901
Treating senile dementia with traditional Chinese medicine. Clinical interventions in aging 20070601
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatric disease and treatment 20070601
[Treatment of thyroid ophthalmopathy--a clinical case]. Oftalmologia (Bucharest, Romania : 1990) 20070101
[Influence of arterial hypertension on the clinical course of Parkinson's disease (PD) among middle-aged patients]. Likars'ka sprava 20070101
[Treatment by medicine which improves cerebral circulation and metabolism]. Nihon rinsho. Japanese journal of clinical medicine 20061128
Supraspinal control of external anal sphincter motility: effects of vesical distension in humans and cats. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20061101
[Nicergoline, ibudilast, ifenprodil tartrate]. Nihon rinsho. Japanese journal of clinical medicine 20061028
An efficient separation and method development for the quantifying of two basic impurities of Nicergoline by reversed-phase high performance liquid chromatography using ion-pairing counter ions. Journal of pharmaceutical and biomedical analysis 20061011
Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chinese medicine 20060101
Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain research 20051220
A phylogenetic survey of biliary lipids in vertebrates. Journal of lipid research 20051001
Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. Brain research 20050614
Differential modulation of microglia superoxide anion and thromboxane B2 generation by the marine manzamines. BMC pharmacology 20050101
[A case of pseudotumorous course of brain demyelinating disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101
[Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus]. Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20050101
Nicergoline reverts haloperidol-induced loss of detoxifying-enzyme activity. European journal of pharmacology 20041128
Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. Journal of the neurological sciences 20041115
Nicergoline enhances glutamate uptake via glutamate transporters in rat cortical synaptosomes. Biological & pharmaceutical bulletin 20040601
Prolongevity medicine: Antagonic-Stress drug in distress, geriatrics, and related diseases. II. Clinical review--2003. Annals of the New York Academy of Sciences 20040601
[Nicergoline-induced Prinzmetal angina. 'Heartache' instead of headache]. Orvosi hetilap 20040104
Sudden hearing loss as a first complication of long-standing Type 1 diabetes mellitus: a case report. Diabetic medicine : a journal of the British Diabetic Association 20040101
Neuroprotection: a realistic goal for aged brain? Advances in experimental medicine and biology 20040101
Nicergoline in the treatment of dizziness in elderly patients. A review. Archives of gerontology and geriatrics. Supplement 20040101
[1-13C]Glucose entry in neuronal and astrocytic intermediary metabolism of aged rats. A study of the effects of nicergoline treatment by 13C NMR spectroscopy. Brain research 20030314
[Neurotransmitter mechanism of the tropoxin effect in comparison with other antimigraine preparations]. Eksperimental'naia i klinicheskaia farmakologiia 20030101
Antioxidant properties of MDL and MMDL, two nicergoline metabolites, during chronic administration of haloperidol. European journal of pharmacology 20021018
First derivative ratio spectrophotometric, HPTLC-densitometric, and HPLC determination of nicergoline in presence of its hydrolysis-induced degradation product. Journal of pharmaceutical and biomedical analysis 20021015
Inhibition by brimonidine of forskolin-induced nitrite production in isolated pig ciliary processes. Investigative ophthalmology & visual science 20020801
Plasticity of GABA(a) system during ageing: focus on vestibular compensation and possible pharmacological intervention. Brain research 20020301
Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion). Neuroscience 20020101
Acute interstitial nephritis due to nicergoline (Sermion). Nephron 20020101
[Nicergoline in the treatment of patients after a mild ischemic stroke]. Neurologia i neurochirurgia polska 20020101
[Sermion in the treatment of patients with neurological diseases]. Voenno-meditsinskii zhurnal 20010801
Effect of an alpha-blocker (Nicergoline) and of a beta-blocker (Acebutolol) on the in vitro biosynthesis of vascular extracellular matrix. Pathologie-biologie 20010501
Immunoassays for the detection of nicergoline and its metabolites in human plasma. Journal of pharmaceutical and biomedical analysis 20010401
Pulmonary function in men after repeated sessions of oxygen breathing at 0.25 MPa for 90 min. Aviation, space, and environmental medicine 20010301
Inhibitory effect of nicergoline on superoxide generation by activated rat microglias measured using a simple chemiluminescence method. Neuroscience letters 20010105
[Current strategies of pathogenetic therapy of Alzheimer's disease]. Vestnik Rossiiskoi akademii meditsinskikh nauk 20010101
Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. The Cochrane database of systematic reviews 20010101
[A case of parkinsonism induced by an oral contraceptive]. No to shinkei = Brain and nerve 19920201
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 19920101
[Pharmacological analysis of memory disorders of different origins]. Biulleten' eksperimental'noi biologii i meditsiny 19890601
Effect of nicergoline on learning and memory. Methods and findings in experimental and clinical pharmacology 19880701
[The effects of nicergoline on the heart rate in the normotensive or spontaneously hypertensive rat. Possible participation of central alpha-1 receptors]. Journal de pharmacologie 19860101
[Nicergoline to reduce intraoperative blood pressure increases in hypertensive patients]. Cahiers d'anesthesiologie 19851101
Centrally mediated cardiovascular effects of nicergoline in the dog compared to those of clonidine. European journal of pharmacology 19851029
[Plasma renin activity and prostaglandin E2 in hypotension induced by nicergoline]. Annales francaises d'anesthesie et de reanimation 19850101
Systemic and carotid haemodynamics and plasma renin activity during deliberate hypotension in dogs: a comparison of sodium nitroprusside with nicergoline. European journal of anaesthesiology 19840301
[Haemodynamic and metabolic effects of exercise test in diabetic patients with arteritis treated or not with nicergoline (author's transl)]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris 19810901
Effects of nicergoline on the cardiovascular system of dogs and rats. Journal of cardiovascular pharmacology 19810101
Some haemodynamic effects of nicergoline, a new alpha-blocking agent, in the closed-chest anaesthetized dog as compared with nitroprusside and nitroglycerin. Arzneimittel-Forschung 19810101
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. Research communications in chemical pathology and pharmacology 19790201
Properties